21 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
20 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
25 Feb 2025 Date | | - Cons. EPS | - EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
23 Aug 2024 Date | | - Cons. EPS | - EPS |
21 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
20 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
25 Feb 2025 Date | | - Cons. EPS | - EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
23 Aug 2024 Date | | - Cons. EPS | - EPS |
Medical - Devices Industry | Healthcare Sector | Dr. Robyn Elliott B.Sc., BSc (Hons), Ph.D. CEO | OTC PINK Exchange | AU000000PNV0 ISIN |
AU Country | 282 Employees | - Last Dividend | - Last Split | - IPO Date |
PolyNovo Limited is an innovative company focused on the development of medical devices, with a global presence that includes the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and other international markets. The company’s key product is the NovoSorb Biodegradable Temporising Matrix, a pioneering solution designed for the management of fully debrided clean surgical wounds. Originating as Calzada Limited, the company underwent a rebranding to PolyNovo Limited in November 2014. Incorporated in 1998, PolyNovo has its headquarters in Port Melbourne, Australia, marking its journey from a national entity into a respected player in the global medical devices industry.